Critical review of Ani Marma of Upper limb with reference to Volkamann’s Ischaemic Contracture

Ayurvedic authorities in the form of Samhitas have given due importance to the knowledge of anatomy. Acharya Sushruta emphasized the importance of anatomical regions of the body, while treating the traumas occurring in war and established the knowledge of these vulnerable structures in Sushruta Sharirasthana 6th chapter as Marma Sthanas. The Marmas of the upper limb need much to care, as a little injury of it can lead to a permanent disability of the limb which can make one’s life miserable. So, these are analysed scientifically and discussed emphatically to reveal the anatomical structures at that level. Symptoms and complications due to injuries of the Marmas are co-related with the injuries to the various structures present around it which is helpful in surgical approaches of the involved structure. In the present review, the symptoms formed due to injury to the Ani Marma of upper limb are presented as Sthabdabahuta i.e., functional deformity of the arm. These effects are correlated to a symptomatology referred as “Volkaman’s Ischaemic Contracture” since the symptoms of both appears to be similar

Synthesis and characterization of nickel oxide nanoparticles by self-propagating low temperature combustion method

Nickel Oxide (NiO) nanoparticles have been synthesised by self-propagating low temperature Combustion synthesis method using Nickel salt with polyethylene glycol as fuel. As synthesized NiO nanoparticles was characterized by employing Fourier transform infrared spectroscopy (FTIR), Scanning Electron Microscopy (SEM), and Energy dispersive X-ray microanalysis studies (EDAX) techniques and X-ray diffraction (XRD) confirmed the formation of NiO nanoparticles in the range 20 to 40 nm. SEM images clearly shows the NiO particles are in Nano size.&nbsp

Photo-Irradiated Biosynthesis of Silver Nanoparticles Using Edible Mushroom Pleurotus florida and Their Antibacterial Activity Studies

This is a report on photo-irradiated extracellular synthesis of silver nanoparticles using the aqueous extract of edible oyster mushroom (Pleurotus florida) as a reducing agent. The appearance, size, and shape of the silver nanoparticles are understood by UV-visible spectroscopy, field emission scanning electron microscopy, transmission electron microscopy, and atomic force microscopy. The X-ray diffraction studies, energy dispersive X-ray analysis indicate that particles are crystalline in nature. Fourier transform infrared spectroscopy analysis revealed that the nanoparticles are covered with biomoieties on their surface. As can be seen from our studies, the biofunctionalized silver nanoparticles thus produced have shown admirable antimicrobial effects, and the synthetic procedure involved is eco-friendly and simple, and hence high range production of the same can be considered for using them in many pharmaceutical applications

Anticonvulsant activity of Bacopa monniera in rodents

Bacopa monniera, da família Scrophulariaceae, e comumente denominada Brahmi, é bem conhecida na Índia por sua atividade no Sistema Nervoso Central, mas seu efeito neurofarmacológico não foi, ainda, explorado. No presente estudo, investigaram-se os efeitos antiepilépticos da planta. O extrato etanólico da Bacopa monniera foi testado quanto à atividade anticonvulsivante em ratos albinos, utilizando-se diferentes modelos de convulsão. O extrato etanólico das folhas produziu atividade anticonvulsivante significativa para todos os diferentes modelos estudados. O presente estudo mostra provável mecanismo de ação semelhante ao dos benzodiazepínicos (agonista do GABA). Assim sendo, esses resultados enfatizam a necessidade de diversificar, utilizando-se abordagens terapêuticas alternativas da medicina natural, em que uma planta facilmente disponível pode fornecer soluções para vários desafios terapêuticos, como o observado na ação anticonvulsivante do extrato etanólico de Bacopa monniera.Bacopa monnieri (L), belonging to the Scrophulariaceae family and commonly known as Brahmi, is well known in India for its CNS activity but its neuropharmacological effect has not yet been explored. In the present study, the antiepileptic effects of the plant were investigated. The ethanolic extract of Bacopa monniera was tested for anticonvulsant activity in albino rats, using different convulsive models. The ethanolic extract of leaves produced significant anticonvulsant activity for all the different models studied. The present study shows a probable mechanism of action similar to that of benzodiazepines (GABA agonist). Thus, these results emphasize the need to diversify by using alternative therapeutic approaches pertaining to herbal medicine, where a single easily available plant may provide solutions to several therapeutic challenges, as observed in the anticonvulsant action of ethanolic extract of B. monniera

Down Regulation of Genes Involved in T Cell Polarity and Motility during the Induction of Heart Allograft Tolerance by Allochimeric MHC I

BACKGROUND:The allochimeric MHC class I molecule [alpha1h1/u]-RT1.Aa that contains donor-type (Wistar Furth, WF; RT1u) epitopes displayed on recipient-type (ACI, RT1a) administered in conjunction with sub-therapeutic dose of cyclosporine (CsA) induces indefinite survival of heterotopic cardiac allografts in rat model. In vascularized transplantation models, the spleen contributes to graft rejection by generating alloantigen reactive T cells. The immune response in allograft rejection involves a cascade of molecular events leading to the formation of immunological synapses between T cells and the antigen-presenting cells. METHODOLOGY/PRINCIPAL FINDINGS:To elucidate the molecular pathways involved in the immunosuppressive function of allochimeric molecule we performed microarray and quantitative RTPCR analyses of gene expression profile of splenic T cells from untreated, CsA treated, and allochimeric molecule + subtherapeutic dose of CsA treated animals at day 1, 3 and 7 of post transplantation. Allochimeric molecule treatment caused down regulation of genes involved in actin filament polymerization (RhoA and Rac1), cell adhesion (Catna1, Vcam and CD9), vacuolar transport (RhoB, Cln8 and ATP6v1b2), and MAPK pathway (Spred1 and Dusp6) involved in tubulin cytoskeleton reorganization and interaction between actin and microtubule cytoskeleton. All these genes are involved in T cell polarity and motility, i.e., their ability to move, scan and to form functional immunological synapse with antigen presenting cells (APCs). CONCLUSIONS:These results indicate that the immunosuppressive function of allochimeric molecule may depend on the impairment of T cells' movement and scanning ability, and possibly also the formation of immunological synapse. We believe that these novel findings may have important clinical implications for organ transplantation

Joint Effect of MCP-1 Genotype GG and MMP-1 Genotype 2G/2G Increases the Likelihood of Developing Pulmonary Tuberculosis in BCG-Vaccinated Individuals

We previously reported that the – 2518 MCP-1 genotype GG increases the likelihood of developing tuberculosis (TB) in non-BCG-vaccinated Mexicans and Koreans. Here, we tested the hypothesis that this genotype, alone or together with the – 1607 MMP-1 functional polymorphism, increases the likelihood of developing TB in BCG-vaccinated individuals. We conducted population-based case-control studies of BCG-vaccinated individuals in Mexico and Peru that included 193 TB cases and 243 healthy tuberculin-positive controls from Mexico and 701 TB cases and 796 controls from Peru. We also performed immunohistochemistry (IHC) analysis of lymph nodes from carriers of relevant two-locus genotypes and in vitro studies to determine how these variants may operate to increase the risk of developing active disease. We report that a joint effect between the – 2518 MCP-1 genotype GG and the – 1607 MMP-1 genotype 2G/2G consistently increases the odds of developing TB 3.59-fold in Mexicans and 3.9-fold in Peruvians. IHC analysis of lymph nodes indicated that carriers of the two-locus genotype MCP-1 GG MMP-1 2G/2G express the highest levels of both MCP-1 and MMP-1. Carriers of these susceptibility genotypes might be at increased risk of developing TB because they produce high levels of MCP-1, which enhances the induction of MMP-1 production by M. tuberculosis-sonicate antigens to higher levels than in carriers of the other two-locus MCP-1 MMP-1 genotypes studied. This notion was supported by in vitro experiments and luciferase based promoter activity assay. MMP-1 may destabilize granuloma formation and promote tissue damage and disease progression early in the infection. Our findings may foster the development of new and personalized therapeutic approaches targeting MCP-1 and/or MMP-1

Hsp72 (HSPA1A) Prevents Human Islet Amyloid Polypeptide Aggregation and Toxicity: A New Approach for Type 2 Diabetes Treatment

Type 2 diabetes is a growing public health concern and accounts for approximately 90% of all the cases of diabetes. Besides insulin resistance, type 2 diabetes is characterized by a deficit in β-cell mass as a result of misfolded human islet amyloid polypeptide (h-IAPP) which forms toxic aggregates that destroy pancreatic β-cells. Heat shock proteins (HSP) play an important role in combating the unwanted self-association of unfolded proteins. We hypothesized that Hsp72 (HSPA1A) prevents h-IAPP aggregation and toxicity. In this study, we demonstrated that thermal stress significantly up-regulates the intracellular expression of Hsp72, and prevents h-IAPP toxicity against pancreatic β-cells. Moreover, Hsp72 (HSPA1A) overexpression in pancreatic β-cells ameliorates h-IAPP toxicity. To test the hypothesis that Hsp72 (HSPA1A) prevents aggregation and fibril formation, we established a novel C. elegans model that expresses the highly amyloidogenic human pro-IAPP (h-proIAPP) that is implicated in amyloid formation and β-cell toxicity. We demonstrated that h-proIAPP expression in body-wall muscles, pharynx and neurons adversely affects C. elegans development. In addition, we demonstrated that h-proIAPP forms insoluble aggregates and that the co-expression of h-Hsp72 in our h-proIAPP C. elegans model, increases h-proIAPP solubility. Furthermore, treatment of transgenic h-proIAPP C. elegans with ADAPT-232, known to induce the expression and release of Hsp72 (HSPA1A), significantly improved the growth retardation phenotype of transgenic worms. Taken together, this study identifies Hsp72 (HSPA1A) as a potential treatment to prevent β-cell mass decline in type 2 diabetic patients and establishes for the first time a novel in vivo model that can be used to select compounds that attenuate h-proIAPP aggregation and toxicity

Investigation of flexural properties of epoxy composite by utilizing graphene nanofillers and natural hemp fibre reinforcement

This study aims to determine the optimum reinforcement required to attain the best combination of flexural strength of modified green composites (graphene oxide + hemp fibre reinforced epoxy composites) for potential use in structural applications. An attempt was also made for the combination of graphene and hemp fibres to enhance load-bearing ability. The infusion of hemp and graphene was made by the weight of the base matrix (epoxy composite). Results showed that graphene reinforcement at 0.4 wt.% of matrix showed load-sustaining capacity of 0.76 kN or 760 MPa. In the case of hemp fibre reinforcement at 0.2 wt.% of the matrix, infusion showed enhanced load-bearing ability (0.79 kN or 790 MPa). However, the combination of graphene (0.1 wt.% graphene nanofillers) and hemp (5 wt.% hemp fibre) indicated a load-sustaining ability of 0.425 kN or 425 MPa, whereas maximum deflection was observed for specimen with hemp 7.5 % + graphene 0.2 % with 1.9 mm. Graphene addition to the modified composites in combination with natural fibres showed promising results in enhancing the mechanical properties under study. Moreover, graphene-modified composites exhibited higher thermal resistance compared to natural fibre reinforced composites. However, when nanofiller reinforcement exceeded a threshold value, the composites exhibited reduced flexural strength as a result of nanofiller agglomeration

2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice

Background Non-adherence to treatment could preclude reaching an optimal outcome. Thirty to 80% of patients with rheumatic and musculoskeletal diseases (RMDs) do not adhere to the agreed treatment. Objectives The objective was to establish points to consider (PtCs) for the prevention, screening, assessment and management of non-adherence to (non-)pharmacological treatments in people with RMDs. Methods An EULAR task force (TF) was established, and the EULAR standardised operating procedures for the development of PtCs were followed. The TF included healthcare providers (HCPs), comprising rheumatologists, nurses, pharmacists, psychologists, physiotherapists, occupational therapists and patient-representatives from 12 European countries. A review of systematic reviews was conducted in advance to support the TF in formulating the PtCs. The level of agreement among the TF was established by anonymous online voting. Results Four overarching principles and nine PtCs were formulated. The PtCs reflect the phases of action on non-adherence. HCPs should assess and discuss adherence with patients on a regular basis and support patients to treatment adherence. As adherence is an agreed behaviour, the treatment has to be tailored to the patients' needs. The level of agreement ranged from 9.5 to 9.9 out of 10. Conclusions These PtCs can help HCPs to support people with RMDs to be more adherent to the agreed treatment plan. The basic scheme being prevent non-adherence by bonding with the patient and building trust, overcoming structural barriers, assessing in a blame-free environment and tailoring the solution to the problem